| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
D-Galacto-D-mannan does not have a specific biological target as it is a plant-derived polysaccharide used as a reference compound and biochemical reagent. Its primary interactions are with enzymes that hydrolyze galactomannans, such as β-mannanase and α-galactosidase. These enzymes are present in various organisms and are involved in the degradation of plant cell wall polysaccharides. The compound's role is as a substrate for studying these enzymes and as a reference for polysaccharide analysis.
|
|---|---|
| ln Vitro |
In vitro activity of D-Galacto-D-mannan is characterized by its use as a substrate for glycoside hydrolases. The compound can be used in enzyme assays to measure the activity of β-mannanase and α-galactosidase. The release of reducing sugars from the polysaccharide can be quantified using colorimetric methods such as the dinitrosalicylic acid (DNS) assay. The compound's water solubility and well-defined structure make it a useful substrate for studying carbohydrate-active enzymes.
|
| ln Vivo |
In vivo biological activity of D-Galacto-D-mannan is limited to its potential as a dietary fiber. Galactomannans are not digested in the human small intestine and can serve as fermentable substrates for gut microbiota, producing short-chain fatty acids. The compound has been associated with various physiological functions, such as promoting the proliferation of intestinal Bifidobacteria, lowering blood pressure and blood sugar, and preventing constipation, colon cancer, and cardiovascular disease.
|
| Enzyme Assay |
Non-cellular experiments for D-Galacto-D-mannan typically involve its use as a substrate or reference compound in enzyme assays. A typical protocol includes dissolving the polysaccharide in buffer and incubating it with the enzyme of interest. The release of reducing sugars is measured using the DNS assay. The compound can also be used as a standard for the analysis of polysaccharide composition by methods such as GC-MS or HPLC after hydrolysis and derivatization.
|
| Cell Assay |
Cell-based assays are not typically performed with D-Galacto-D-mannan, as it is primarily used as a reference compound and substrate for enzyme studies. However, its effects on gut microbiota can be studied in vitro using fecal fermentation models. The compound is not tested in mammalian cell culture models for pharmacological activity. Its applications are primarily in carbohydrate chemistry and food science.
|
| Animal Protocol |
In vivo animal studies with D-Galacto-D-mannan are limited to its evaluation as a dietary fiber. Animal models can be used to study the effects of galactomannan consumption on gut microbiota composition, lipid metabolism, and glucose homeostasis. However, the compound is not used as a therapeutic agent, and its primary applications are in food and nutritional research.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of D-Galacto-D-mannan are not extensively characterized, as it is a dietary fiber and not a therapeutic agent. The compound has a high molecular weight and is not absorbed in the gastrointestinal tract. It is fermented by gut microbiota, producing short-chain fatty acids. No data on systemic absorption or distribution are available, as the compound does not enter the bloodstream.
|
| Toxicity/Toxicokinetics |
Toxicological data for D-Galacto-D-mannan indicate that it is generally recognized as safe for use in food products. As a dietary fiber, it is well-tolerated at normal consumption levels. High doses may cause gastrointestinal discomfort due to its fermentable nature. No carcinogenic or reproductive toxicity data are available. The compound is considered safe for use in food and research applications.
|
| Additional Infomation |
Galactomannan is a heteropolysaccharide composed of a mannan backbone and galactose side chains. It has been reported that galactomannan is found in Antrodia camphorata, edible mushrooms, and other organisms with relevant data.
D-Galacto-D-mannan is a plant-derived polysaccharide used as a reference compound and biochemical reagent. Its CAS number is 11078-30-1. The compound is available with a purity of ≥94% from various suppliers. It is used in the analysis of plant cell wall polysaccharides and as a substrate for glycoside hydrolases. The compound is not approved for therapeutic use but is an important tool for carbohydrate research. It should be stored in a cool, dry place. |
| Molecular Formula |
C18H32O16
|
|---|---|
| Molecular Weight |
504.437
|
| Exact Mass |
504.169
|
| CAS # |
11078-30-1
|
| PubChem CID |
439336
|
| Appearance |
White to off-white solid powder
|
| Density |
1.8±0.1 g/cm3
|
| Boiling Point |
860.9±65.0 °C at 760 mmHg
|
| Flash Point |
474.4±34.3 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.673
|
| LogP |
-5.88
|
| Hydrogen Bond Donor Count |
11
|
| Hydrogen Bond Acceptor Count |
16
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
34
|
| Complexity |
641
|
| Defined Atom Stereocenter Count |
15
|
| SMILES |
O([C@H]1[C@H]([C@H]([C@@H]([C@@H](CO)O1)O)O)O)[C@H]1[C@@H]([C@@H]([C@H](O)O[C@@H]1CO[C@@H]1[C@@H]([C@H]([C@H]([C@@H](CO)O1)O)O)O)O)O
|
| InChi Key |
OMDQUFIYNPYJFM-XKDAHURESA-N
|
| InChi Code |
InChI=1S/C18H32O16/c19-1-4-7(21)9(23)13(27)17(32-4)30-3-6-15(11(25)12(26)16(29)31-6)34-18-14(28)10(24)8(22)5(2-20)33-18/h4-29H,1-3H2/t4-,5-,6-,7+,8-,9+,10+,11-,12+,13-,14+,15-,16-,17+,18+/m1/s1
|
| Chemical Name |
(2R,3R,4S,5R,6S)-2-(hydroxymethyl)-6-[[(2R,3S,4R,5S,6R)-4,5,6-trihydroxy-3-[(2S,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9824 mL | 9.9120 mL | 19.8240 mL | |
| 5 mM | 0.3965 mL | 1.9824 mL | 3.9648 mL | |
| 10 mM | 0.1982 mL | 0.9912 mL | 1.9824 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Link: https://clinicaltrials.gov/ct2/show/NCT05096052
Conditions:COVID-19|COVID-19 Pandemic|COVID-19 Respiratory Infection|SARS-CoV2 Infection|Cytokine Release SyndromeProducts are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
